RE: RE: Cowen Conference Presentation I would recommend hedging your bet and pick up some Nymox (Q-NYMX shares), rather than adding more PRX to your portfolio. The Nymox share price has held up fairly well in the $8.10 range as they progress through two Phase III pivotal studies with their BPH drug NX-1207. I wish we would see the same share support for PRX as new milestones are attained.